Research

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds

Eye injection drugs recommended by NICE cost the NHS up to £447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others.

UK health spending needs to grow faster than GDP

The NHS is frequently in the news about its ongoing funding crisis. New research suggests demand for health services is set to continue to grow faster than GDP per head in all developed countries around the world. Along with a paper about the J-value model for life-expectancy growth in industrialised countries, the research establishes a reason why people in the UK will want to spend an increasing fraction of their income on health services.